05/23/2002 By David Loshak
Anti-E-selectin is ineffective in the treatment of chronic plaque psoriasis even though it is a well-tolerated, logical and safe therapy.
This finding of a randomised trial is reported by dermatologists and other specialists based at the University of Manchester, Salford, England.
The doctors noted that skin-homing, memory T lymphocytes play an important part in the pathogenesis of psoriasis by interacting with the vascular addressin, E-selectin and trafficking into lesional skin. This suggested blockade of skin-homing T cells with an antibody directed at E-selectin as an attractive option for targeted therapy of the disease.
A multicentre, randomised, placebo-controlled trial to investigated the clinical efficacy and side-effects of a humanised monoclonal antibody to E-selectin, CDP850, for moderate to severe chronic plaque psoriasis. Nine men aged 25-47 years received 20 mg/Kg-1 CDP850 intravenously as a single dose and three men and one woman aged 25-50 years received placebo infusions.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!